Territorial Availability: Available through Bertin Technologies only in France
- Correlated keywords
- TMEM-173 MITA Methionine-Proline-Tyrosine-Serine plasma membrane tetraspanner IRF-3 ? NET-23 R-293Q NFkB R-232 escherichia eris hsting mp?s net23 savi transmembrane protein 173 Q86WV6 HEK-293T Mitochondrial Mediator of IRF3 Activation G-230A cdigmp cdiamp cgmpamp H-232 mutant
- Product Overview:
STING AQ variant (human recombinant) contains amino acids 138-379 of the wild-type STING variant (R232) with an alanine substituted for glycine at position 230 and a glutamine substituted for arginine at position 293. Stimulator of interferon genes (STING) is a component of the innate immune response that binds to cyclic dinucleotides, which are bacterial second messengers.{24607} Recognition of cyclic-di-GMP (c-di-GMP), c-di-AMP, or c-GMP-AMP leads to activation of NF-?B and transcription of immunomodulatory genes, including type I interferons (IFN).{22400,22401,24611} The R232 variant of STING is the most common variant in the human population, found at a frequency of 57.9% in the 1000 Genome Project.{38697} The SNP variant H232 is found at a 13.7% frequency. The G230A, R293Q double mutation occurs in 5.2% of the human population and when expressed in HEK293T cells, this mutation reduces the IFN response to bacterial ligands by 30-40% compared to wild-type STING. Whereas the R293Q substitution alone is severely defective in response to bacterial cyclic dinucleotides, the G230A substitution is thought to help maintain some ability of this variant to respond to bacterial cyclic dinucleotides. Based on crystal structure of STING, the G230A mutation alters the conformation of the lid region that clamps onto the c-di-GMP, however, the R293 residue does not directly bind to c-di-GMP.{38697} The R293Q mutation may instead disrupt STING activity indirectly by altering the function of a nearby cysteine residue required for IFN-? expression.{38698}
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.